BioSpace News Archive

The Partnership to Fight Chronic Disease (PFCD) today released, “Quantifying Impact of Accelerated Approval Drugs on Medicaid Spending: De Minimus Impact, Maximum Attention,” an economic analysis examining the impact of the Food and Drug Administration’s accelerated approval pathway on Medicaid spending.

Webster Dental Care, an industry leading dental service organization with eleven locations, welcomes Dr. Michelle Pelc to its expert team.

After more than three decades of research, scientists have proven that the cancer affecting up to one in four adult California sea lions that received a necropsy, or animal autopsy, at The Marine Mammal Center in Sausalito, CA, is caused by a sexually transmitted herpesvirus

Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a manufacturing agreement expansion with AstraZeneca to include drug product manufacturing.

The Government of Canada is committed to reducing the spread of COVID-19 and the variants of concern in Canada. Self-isolation is one of the most effective ways to help stop the spread of COVID-19.

American Rheumatology Network (ARN) today launched ARN Clinical Research to transform drug development efforts in rheumatology research in partnership with Trio Health, a leading real-world technology solutions provider.

Illumina, Inc. (NASDAQ: ILMN), today announced that it disagrees with, and will oppose, the U.S. Federal Trade Commission (FTC)’s challenge to its previously announced acquisition of GRAIL, a pre-commercial company founded to accelerate early screening of cancer.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced its 2021 clinical plans and reported financial results for the fourth quarter and year ended December 31, 2020.

Eledon Pharmaceuticals, Inc., (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with an autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today reported its fourth quarter and full-year 2020 operating and financial results.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.